Citi Downgrades Arcturus Therapeutics (ARCT) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St futures slide as rising oil, yields dampen mood
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
Tweet
Share
E-mailGet Alerts ARCT Hot Sheet
Price: $12.77 +0.08%
Rating Summary:
14 Buy, 4 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 15 | New: 25
Rating Summary:
14 Buy, 4 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 15 | New: 25
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz downgraded Arcturus Therapeutics (NASDAQ: ARCT) from Buy to Neutral with a price target of $12.00.
For an analyst ratings summary and ratings history on Arcturus Therapeutics click here. For more ratings news on Arcturus Therapeutics click here.
Shares of Arcturus Therapeutics closed at $11.54 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TD Cowen Starts Versamet Royalties (VMET:CN) at Buy
- Alphabet (GOOG) PT Raised to $485 at TD Cowen
- Saratoga Investment (SAR) PT Lowered to $18 at Compass Point
Create E-mail Alert Related Categories
DowngradesRelated Entities
Citi, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
